

Date: July 03, 2023

To,
Company Secretary & Compliance Officer
Remus Pharmaceuticals Limited

Dear Sir,

Sub: Investor Grievance Report for the quarter ended 30.06.2023.


Unit: Remus Pharmaceuticals Limited

Please refer the below investor grievance details for the period, starting from 01.04.2023 to 30.06.2023.

Investor grievance report for the quarter ended 30.06.2023						
Particulars	SEBI	BSE	NSE	Letters	Mails	Total
Pending at the beginning of the quarter	Nil	Nil	Nil	Nil	Nil	Nil
Received during the quarter	Nil	Nil	Nil	Nil	Nil	Nil
Disposed of during the quarter	Nil	Nil	Nil	Nil	Nil	Nil
Remaining unresolved at the end of the quarter	Nil	Nil	Nil	Nil	Nil	Nil

Thanking You,

For Link Intime India Pvt Ltd


Rachita Somani
Branch Head – Ahmedabad

